Literature DB >> 2291597

[Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine].

H Debray1, J Guihard, D Peyramond, P Tron.   

Abstract

The effectiveness and tolerance of alizapride and metopimazine used to treat vomiting induced by acute infectious diseases were evaluated in 47 infants and children seen in five hospitals. Patients were randomized to alizapride (n = 23) or metopimazine (n = 24). Medications were given orally (drops) for 3 to 5 days. All the patients were monitored until the end of the study period. Effectiveness was excellent or good in both groups with no statistically significant difference. Clinical tolerance was outstanding in both groups; one patient in the alizapride group exhibited transient, mild drowsiness after the doses. This study confirms the good risk/benefit ratio of alizapride in the treatment of emesis in infants and children.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291597

Source DB:  PubMed          Journal:  Ann Pediatr (Paris)        ISSN: 0066-2097


  5 in total

1.  Dose-finding study of oral metopimazine.

Authors:  J Herrstedt; T Sigsgaard; H R Angelo; J P Kampmann; M Hansen
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design.

Authors:  P C Nathan; G Tomlinson; L L Dupuis; M L Greenberg; S Ota; U Bartels; B M Feldman
Journal:  Support Care Cancer       Date:  2005-07-29       Impact factor: 3.603

Review 3.  Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.

Authors:  Zbys Fedorowicz; Vanitha A Jagannath; Ben Carter
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

Review 4.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.